drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
Autologous, gene-modified T cells expressing a mesothelin-specific CAR and engineered to secrete PD-1 nanobodies to enhance antitumor activity by CAR-mediated cytotoxicity and local PD-1/PD-L1 blockade.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a mesothelin-specific CAR mediate targeted tumor cell killing; the cells also secrete PD-1 nanobodies that locally block the PD-1/PD-L1 checkpoint to enhance CAR T activation, persistence, and antitumor efficacy in mesothelin-positive tumors.
drug_name
BZT2312 “Fast” CAR T cells
nct_id_drug_ref
NCT06249256